This work describes a site-directed mutagenesis study of pentaerythritol tetranitrate reductase (PETN reductase) to probe the role of key active site residues in influencing both product enantiopurity and the ratio of CC vs. nitro-group reduction with 2-phenyl-1-nitropropene. Comparative biotransformations of wild type and single/double mutants of PETN reductase with 2-phenyl-1-nitropropene showed that one enzyme scaffold was capable of generating both enantiomeric products with improved enantiopurities by a manipulation of the reaction conditions and/or the presence of a one or two key mutations. These changes located at key active site residues were sufficient to moderately improve product enantiopurity, cause a switch in the major product enantiomer formed and/or promote or eliminate side-product formation. The mutation of substrate-binding residue Y351 to alanine and phenylalanine improved the biocatalytic potential of PETN reductase by the elimination of a competing side reaction. The crystal structures of three mutants at residue Y351 (PDB codes: 3P81, 3P84 and 3P8J) show that only subtle changes in the active site environment may be necessary to generate significantly improved biocatalysts.
No takes yet. Share an insight, caveat, or question.
Fryszkowska et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: